The starting point for many of our studies arises from the analysis of samples and data from patients. Developing and applying several different tools, including neuroimaging analysis, metabolomics and proteomics, we seek to identify biomarkers of neurological disease. Promising candidates may become diagnostic or prognostic biomarkers. However, our primary goal is to leverage biomarkers to study the biological and pathological events following acute stroke. In this regard, our biomarker studies guide our subsequent hypotheses about mechanisms of secondary brain injury.
Below are some examples of our work on biomarker development.
